JP2022512882A5 - - Google Patents

Info

Publication number
JP2022512882A5
JP2022512882A5 JP2021523715A JP2021523715A JP2022512882A5 JP 2022512882 A5 JP2022512882 A5 JP 2022512882A5 JP 2021523715 A JP2021523715 A JP 2021523715A JP 2021523715 A JP2021523715 A JP 2021523715A JP 2022512882 A5 JP2022512882 A5 JP 2022512882A5
Authority
JP
Japan
Prior art keywords
manipulated
population
cells
sequence
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021523715A
Other languages
English (en)
Japanese (ja)
Other versions
JP7553440B2 (ja
JP2022512882A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/001194 external-priority patent/WO2020095107A1/en
Publication of JP2022512882A publication Critical patent/JP2022512882A/ja
Publication of JP2022512882A5 publication Critical patent/JP2022512882A5/ja
Application granted granted Critical
Publication of JP7553440B2 publication Critical patent/JP7553440B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021523715A 2018-11-07 2019-11-07 抗cd33免疫細胞癌療法 Active JP7553440B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201862756718P 2018-11-07 2018-11-07
US62/756,718 2018-11-07
US201862767388P 2018-11-14 2018-11-14
US201862767395P 2018-11-14 2018-11-14
US62/767,395 2018-11-14
US62/767,388 2018-11-14
US201962826648P 2019-03-29 2019-03-29
US201962826643P 2019-03-29 2019-03-29
US62/826,643 2019-03-29
US62/826,648 2019-03-29
PCT/IB2019/001194 WO2020095107A1 (en) 2018-11-07 2019-11-07 Anti-cd33 immune cell cancer therapy

Publications (3)

Publication Number Publication Date
JP2022512882A JP2022512882A (ja) 2022-02-07
JP2022512882A5 true JP2022512882A5 (cg-RX-API-DMAC7.html) 2022-11-15
JP7553440B2 JP7553440B2 (ja) 2024-09-18

Family

ID=69159803

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021523715A Active JP7553440B2 (ja) 2018-11-07 2019-11-07 抗cd33免疫細胞癌療法

Country Status (12)

Country Link
US (1) US20220226375A1 (cg-RX-API-DMAC7.html)
EP (1) EP3877414A1 (cg-RX-API-DMAC7.html)
JP (1) JP7553440B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210089712A (cg-RX-API-DMAC7.html)
CN (1) CN113227141A (cg-RX-API-DMAC7.html)
AU (1) AU2019377892A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021008041A2 (cg-RX-API-DMAC7.html)
CA (1) CA3118816A1 (cg-RX-API-DMAC7.html)
IL (1) IL282286A (cg-RX-API-DMAC7.html)
MX (1) MX2021005398A (cg-RX-API-DMAC7.html)
SG (1) SG11202103832SA (cg-RX-API-DMAC7.html)
WO (1) WO2020095107A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102709603B1 (ko) 2017-02-28 2024-09-27 보르 바이오파마 인크. 계통 특이적 단백질의 억제를 위한 조성물 및 방법
US20210017277A1 (en) * 2018-03-14 2021-01-21 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Anti-cd33 chimeric antigen receptors and their uses
CA3110837A1 (en) 2018-08-28 2020-03-05 Vor Biopharma Inc. Genetically engineered hematopoietic stem cells and uses thereof
AU2020280103A1 (en) * 2019-05-23 2021-12-23 Vor Biopharma Inc. Compositions and methods for CD33 modification
AU2020307667A1 (en) 2019-06-27 2022-01-20 Crispr Therapeutics Ag Use of chimeric antigen receptor T cells and NK cell inhibitors for treating cancer
PH12022550548A1 (en) 2019-09-06 2023-11-20 Crispr Therapeutics Ag Genetically engineered t cells having improved persistence in culture
KR20230074515A (ko) 2020-09-23 2023-05-30 크리스퍼 테라퓨틱스 아게 개선된 기능성 및 지속성을 갖는 붕괴된 레그나제-1 및/또는 tgfbrii를 지니는 유전자 조작된 t 세포
AU2021372458A1 (en) * 2020-10-26 2023-06-15 Research Institute At Nationwide Children's Hospital Chimeric antigen receptor (car) nk cells and uses thereof
WO2022137181A1 (en) 2020-12-23 2022-06-30 Crispr Therapeutics Ag Co-use of lenalidomide with car-t cells
EP4305153A1 (en) 2021-03-09 2024-01-17 CRISPR Therapeutics AG Genetically engineered t cells with ptpn2 knockout have improved functionality and anti-tumor activity
US20230346836A1 (en) 2021-12-22 2023-11-02 Crispr Therapeutics Ag Genetically engineered t cells with disrupted casitas b-lineage lymphoma proto-oncogene-b (cblb) and uses thereof
WO2024023801A2 (en) 2022-07-29 2024-02-01 Crispr Therapeutics Ag Genetically engineered immune cells having disrupted transporter associated with antigen processing-1 (tap-1) gene
WO2024023802A2 (en) 2022-07-29 2024-02-01 Crispr Therapeutics Ag Genetically engineered immune cells having disrupted transporter associated with antigen processing-2 (tap-2) gene
WO2024023804A2 (en) 2022-07-29 2024-02-01 Crispr Therapeutics Ag Genetically engineered immune cells having disrupted transporter associated with antigen processing binding protein (tapbp) gene
WO2024192108A1 (en) 2023-03-14 2024-09-19 Evolveimmune Therapeutics, Inc. Genetically modified car t cells and methods of making and using the same

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
GB9710807D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
US6140081A (en) 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
HK1052372A1 (zh) 2000-02-24 2003-09-11 Xcyte Therapies, Inc. 细胞的同步刺激和富集
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
JP2002060786A (ja) 2000-08-23 2002-02-26 Kao Corp 硬質表面用殺菌防汚剤
US20040224385A1 (en) 2001-08-20 2004-11-11 Barbas Carlos F Zinc finger binding domains for cnn
DK1578446T3 (en) * 2002-11-07 2015-06-29 Immunogen Inc ANTI-CD33 ANTIBODIES AND PROCEDURES FOR TREATING ACUTE MYELOID LEUKEMIA BY USING IT
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US7972854B2 (en) 2004-02-05 2011-07-05 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
PT2816112T (pt) 2009-12-10 2018-11-20 Univ Iowa State Res Found Inc Modificação do adn modificada pelo efector tal
KR101870555B1 (ko) * 2011-08-23 2018-06-22 로슈 글리카트 아게 T 세포 활성화 항원 및 종양 항원에 대해 특이적인 이중특이적 항체 및 이의 사용 방법
WO2013026837A1 (en) * 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
US20130309223A1 (en) * 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
WO2014131694A1 (en) * 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
HK1220698A1 (zh) * 2013-03-13 2017-05-12 Seattle Genetics, Inc. 环糊精和抗体药物偶联物制剂
RU2752933C2 (ru) * 2014-03-11 2021-08-11 Селлектис Способ создания т-клеток, пригодных для аллогенной трансплантации
ES2765710T3 (es) * 2014-04-03 2020-06-10 Cellectis Receptores de antígeno quimérico específicos de CD33 para la inmunoterapia del cáncer
JP6831777B2 (ja) * 2014-07-21 2021-02-17 ノバルティス アーゲー Cd33キメラ抗原受容体を使用する癌の処置
KR102546296B1 (ko) * 2014-10-31 2023-06-21 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 변형된 t 세포에서 유전자 발현의 변경 및 그의 용도
WO2016142532A1 (en) * 2015-03-11 2016-09-15 Cellectis Methods for engineering allogeneic t cell to increase their persistence and/or engraftment into patients
CA2994746A1 (en) * 2015-08-11 2017-02-16 Cellectis Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation
IL258491B2 (en) * 2015-10-16 2023-09-01 Univ Columbia Preparations and methods for inhibiting antigens of a particular lineage
WO2018073393A2 (en) * 2016-10-19 2018-04-26 Cellectis Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
CN110352068A (zh) * 2016-12-02 2019-10-18 南加利福尼亚大学 合成的免疫受体及其使用方法
AU2018220734B2 (en) * 2017-02-20 2025-03-06 Dragonfly Therapeutics, Inc. Proteins binding CD33, NKG2D and CD16
CN107746831B (zh) * 2017-11-07 2019-04-23 南京北恒生物科技有限公司 具有化疗药物抗性的通用型cart/tcrt细胞及其构建方法

Similar Documents

Publication Publication Date Title
JP2021522820A5 (cg-RX-API-DMAC7.html)
JP2022513586A5 (cg-RX-API-DMAC7.html)
CN107709548B (zh) 用于增强治疗性免疫细胞的功效的方法
CN112390892B (zh) 一种嵌合抗原受体以及表达该嵌抗原受体的免疫效应细胞
JP2022509017A5 (cg-RX-API-DMAC7.html)
JP2022115932A5 (cg-RX-API-DMAC7.html)
KR102859548B1 (ko) 메소텔린 양성 암을 치료하기 위한 조성물 및 방법
JP2023542348A5 (cg-RX-API-DMAC7.html)
JP2016514462A5 (cg-RX-API-DMAC7.html)
JP7471289B2 (ja) 抗liv1免疫細胞癌療法
JP2021525524A5 (cg-RX-API-DMAC7.html)
JP2021503006A5 (cg-RX-API-DMAC7.html)
JP2018508215A5 (cg-RX-API-DMAC7.html)
JP2018536436A5 (cg-RX-API-DMAC7.html)
JP2023514407A5 (cg-RX-API-DMAC7.html)
US20170081411A1 (en) Regulatable chimeric antigen receptor
CN114585645A (zh) 对杂合性丧失作出响应的细胞表面受体
US20240269283A1 (en) Antigen-binding polypeptide targeting b7h3 and application thereof
JP2017500869A5 (cg-RX-API-DMAC7.html)
KR20180099768A (ko) 증진된 효능을 갖는 면역 이펙터 세포 요법
CN107735407A (zh) 治疗剂
JP2024097924A (ja) 抗ptk7免疫細胞癌療法
CN107106670A (zh) 用于修饰的t细胞的方法和组合物
JP2024097924A5 (cg-RX-API-DMAC7.html)
JP2016520074A5 (cg-RX-API-DMAC7.html)